Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients (ANTHICUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00543894
First received: October 11, 2007
Last updated: August 11, 2008
Last verified: June 2007
  Purpose

Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A prospective, observational, multicenter study (ANTHICUS).


Condition
Infection in ICU

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients. A Prospective, Observational, Multicenter Study (ANTHICUS)

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Secondary Outcome Measures:
  • the frequency of appropriate antibiotic therapy (defined as the use of antibiotic(s) with "in vitro" efficacy against the identified pathogens responsible for the infection)
  • the frequency of "the strategy of de-escalation" according to the culture results

Enrollment: 500
Study Start Date: February 2006
  Eligibility

Criteria

Inclusion Criteria:

  • Patients with hospital-acquired infections and hospitalised in the ICU at one moment of their hospital stay
  • Hospital-acquired infections accounting for eligibility are:

    • nosocomial pneumonia (including ventilator-associated pneumonia)
    • bacteremia
    • intra-abdominal infections
    • urosepsis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00543894

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Pr Vogelaers UZ Gents
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00543894     History of Changes
Other Study ID Numbers: SRP-HB-MER-2005/1
Study First Received: October 11, 2007
Last Updated: August 11, 2008
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:
Antibiotic, ICU, hospital acquired infection.

Additional relevant MeSH terms:
Communicable Diseases
Cross Infection
Infection
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014